Teva Pharmaceuticals
TEVA
822 hedge funds and large institutions have $30.2B invested in Teva Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 107 funds opening new positions, 277 increasing their positions, 300 reducing their positions, and 46 closing their positions.
133% more first-time investments, than exits
New positions opened: 107 | Existing positions closed: 46
26% more funds holding in top 10
Funds holding in top 10: 47 → 59 (+12)
24% more call options, than puts
Call options by funds: $747M | Put options by funds: $601M
12% more capital invested
Capital invested by funds: $27B → $30.2B (+$3.19B)
6% more funds holding
Funds holding: 773 → 822 (+49)
2.15% more ownership
Funds ownership: 52.74% → 54.89% (+2.1%)
8% less repeat investments, than reductions
Existing positions increased: 277 | Existing positions reduced: 300
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$396M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
+$341M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$266M |
| 4 |
Neuberger Berman Group
New York
|
+$195M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$148M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$357M |
| 2 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$273M |
| 3 |
PC
PointState Capital
New York
|
-$128M |
| 4 |
D.E. Shaw & Co
New York
|
-$90.8M |
| 5 |
SFM
Soros Fund Management
New York
|
-$76.4M |
TEVA Hedge Fund Activity: Q4 2014 in Review
822 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2014, worth a combined $30.2B — up 12% from $27B a quarter earlier.
Buyers outnumbered sellers: 107 funds opened new TEVA positions and 46 closed out — a net gain of 61 holders — while 277 added to existing stakes and 300 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $396M. The largest seller was Capital Research Global Investors, cutting an estimated $357M.
- 822 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2014, up from 773 in Q3 2014.
- Funds reported $30.2B of Teva Pharmaceuticals stock for Q4 2014, up 12% quarter-over-quarter.
- 107 funds opened new Teva Pharmaceuticals positions in Q4 2014 and 46 closed out, a net change of +61 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $396M added.
- The largest Teva Pharmaceuticals seller in Q4 2014 was Capital Research Global Investors, an estimated $357M sold.
Based on aggregated 13F filings for Q4 2014.